期刊文献+

MUC1/CD_3BsAb介导的LAK细胞对MCF-7细胞的体外杀伤作用

Effect of LAK cells mediated by MUC1/CD_3 BsAb on MCF-7 cells in vitro
下载PDF
导出
摘要 目的观察MUC1/CD3双特异性抗体(BsAb)介导下淋巴因子激活的杀伤细胞(LAK细胞)对过度表达MUC1基因的乳腺癌MCF-7细胞株的杀伤作用。方法化学耦连法制备MUC1/CD3双特异性抗体(BsAb)。显微镜下计数A组(BsAb+MCF-7+LAK)、B组(a-CD3+MCF-7+LAK)、C组(a-MUC1+MCF-7+LAK)、D组(a-CD3+a-MUC1+MCF-7+LAK)及E组(RPMI1640培养基+MCF-7+LAK)LAK-MCF-7细胞数目,并计算LAK细胞与MCF-7细胞的结合率。MTT法检测各组LAK细胞对MCF-7细胞的杀伤率。结果A组MCF-7细胞和LAK细胞的结合率及LAK细胞对MCF-7细胞的杀伤率均明显高于B、C、D、E组(P均<0.05)。结论MUC1/CD3BsAb能显著提高LAK细胞与乳腺癌MCF-7细胞的结合率,并显著提高LAK细胞对乳腺癌MCF-7细胞的杀伤率。 [Objective] To observe the regulatory effects of LAK cells mediated by MUC1/CD3 BsAb on MCF-7 breast cancer ceils in vitro. I-Methods7 MUC1/CD3 BsAb wos established by,chemical conjugating of CD3 McAb and MUC1 McAb. The combination of LAK cells and MCF-7 breast cancer cells was obstrved in A group (BASb+MCF-7+LAK),B group(a-CD3+MCF-7A-LAK),C group(a-MUC1+MCF-7+LAK),D group(a-CD3 + a-MUC1+MCF-7A-LAK)and E group(RPMI1640+MCF-7+LAK). Cytotoxicity of LAK cells to MCF-7 cells was observed by MTT assay.[Results] The combination rate of LAK cells and MCF-7 cells and the cytotoxicity activity of LAK cells against MCF-7 breast cancer cells induced by BsAb were significantly higer than B group,C group ,D group and E group ( P 〈 0. 05). [Conclusion] BsAb could can ingrease the combination rates of LAK cells and MCF-7 breast cancer cells,and increase the cytotoxicity of LAK cells against MCF-7 breast cancer cells.
出处 《山东医药》 CAS 北大核心 2007年第9期18-19,共2页 Shandong Medical Journal
基金 河北省科技厅科技攻关项目(052761565)
关键词 黏蛋白1 双特异性抗体 乳腺肿瘤 免疫疗法 mueoproteinl bispecifie antibody breast carcinoma immutherapy
  • 相关文献

参考文献4

二级参考文献15

  • 1Yarden Y, Baselga J, Miles D. Molecular approach to breast cancer treatment. Semin Oncol. 2004, 31 : 6-13.
  • 2Sen M, Wankowski DM, Garlie NK, et al. Use of anti-CD3 x anti-HER2/neu bispeeifie antibody for redirecting cytotoxicity of activated T cells toward HER2/neu + tumors. J Hematother Stem Cell Res, 2001,10 : 247-260.
  • 3Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res, 1999, 58: 2825-2831.
  • 4Yakes FM, Chinratanalab W, Ritter CA, et al. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibodymediated effects on p27, cyclin D1, and antitumor action. Cancer Res,2002, 62:4132-4141.
  • 5Carter P, Ridgway J, Zhu Z. Toward the production of bispecific antibody fragments for clinical applications[J]. J Hematother, 1995, 4(5):463-470.
  • 6Jost CR, Titus JA, Kurucz I. et al. A single-chain bispecific Fv-2 molecule produced in m3anmalian cells redirects lysis by activated CTL[J]. Mol Immnol, 1996, 33(2):211-219.
  • 7Rodriguea ML, Presta LG, Kotts CE, et al. Development of a humanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin dexorubicin prodrug[J]. Cancer Res, 1995, 55(1): 63-70.
  • 8Rozemuller H, Chowdhury PS, Pastan I, et al, Isolation of new anti-CD30 scFvs from DNA-immunized mice by phage display and biologic activity of recombinant immunotoxins produced by fusion with truncated pseudomonas exotoxin[J]. Int J Cancer, 2001, 92(6):861-870.
  • 9Pullarkat V, Deo Y, Link J, et al. A phase I study of HER2/neo bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neo [J]. Cancer Immnunol Immunother, 1999,48(1):9-21.
  • 10Smans KA, Ingvarsson MB, Lindgren P, el al, Bispecific antibodymediated lysis of primary cultures of ovarian carcinoma cells using multiple target antigens[J], Int J Cancer, 1999,83(2):270-277.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部